Full Press Release Details
Bio Announces 1-for-15 Reverse Stock Split
CA - April 3, 2024 - Palisade Bio, Inc. (Nasdaq: PALI), ("Palisade", "Palisade Bio" or
the "Company"), a biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with
autoimmune, inflammatory, and fibrotic diseases, today announced a 1-for-15 reverse split of its common stock, par value $0.01 ("Common
Stock"), effective at 5:00 PM ET on Friday April 5, 2024. Beginning on Monday, April 8, 2024, the Company's Common Stock
will continue to trade on The Nasdaq Capital Market ("Nasdaq") on a split adjusted basis under the trading symbol "PALI,"
but will trade under the following new CUSIP number starting April 8, 2024: 696389402.
reverse stock split was approved by Palisade Bio's stockholders at the virtual special meeting of stockholders held on March 25,
2024. The reverse stock split is primarily intended to increase the Company's per share trading price and bring the Company into
compliance with the Nasdaq's listing requirement regarding minimum share price.
a result of the reverse stock split, every 15 shares of Common Stock issued and outstanding as of the effective date will be automatically
combined into one share of Common Stock. Outstanding warrants, equity-based awards and other outstanding equity rights will be proportionately
adjusted by dividing the shares of Common Stock underlying the securities by 15 and multiplying the exercise/conversion price, as the
case may be, by 15. No fractional shares will be issued as a result of the reverse stock split. Stockholders of record otherwise entitled
to receive a fractional share as a result of the reverse stock split will receive a cash payment in lieu of such fractional shares. The
par value of the Common Stock will remain unchanged at $0.01 per share after the reverse split. The reverse split affects all stockholders
uniformly and will not alter any stockholder's percentage interest in the Company's equity, except to the extent that the
reverse split results in some stockholders owning a fractional share as described above.
information concerning the reverse stock split can be found in Palisade Bio's definitive proxy statement filed with the Securities
and Exchange Commission on February 6, 2024.
Bio is a biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory,
and fibrotic diseases. The Company believes that by using a targeted approach with its novel therapeutics it will transform the treatment
landscape. For more information, please go to www.palisadebio.com.
communication contains "forward-looking" statements for purposes of the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. Forward-looking statements include statements regarding the Company's intentions, beliefs, projections,
outlook, analyses or current expectations concerning, among other things: the extent of our cash runway; our ability to successfully
develop our licensed technologies; estimates about the size and growth potential of the markets for our product candidates, and our ability
to serve those markets, including any potential revenue generated; future regulatory, judicial, and legislative changes or developments
in the United States (U.S.) and foreign countries and the impact of these changes; our ability to maintain the Nasdaq listing of our
securities; our ability to build a commercial infrastructure in the U.S. and other markets; our ability to compete effectively in a competitive
industry; our ability to identify and qualify manufacturers to provide API and manufacture drug product; our ability to enter into commercial
supply agreements; the success of competing technologies that are or may become available; our ability to attract and retain key scientific
or management personnel; the accuracy of our estimates regarding expenses, future revenues, capital requirements and needs for additional
financing; our ability to obtain funding for our operations; our ability to attract collaborators and strategic partnerships; and the
impact of the COVID-19 pandemic or any global event on our business, and operations, and supply. Any statements contained in this communication
that are not statements of historical fact may be deemed to be forward-looking statements. These forward-looking statements are based
upon the Company's current expectations. Forward-looking statements involve risks and uncertainties. The Company's actual
results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these
risks and uncertainties, which include, without limitation, the Company's ability to advance its nonclinical and clinical programs,
the uncertain and time-consuming regulatory approval process; and the Company's ability to secure additional financing to fund
future operations and development of its product candidates. Additional risks and uncertainties can be found in the Company's Annual
Report on Form 10-K for the fiscal year ended December 31, 2023, filed with the Securities and Exchange Commission ("SEC")
on March 26, 2024. These forward-looking statements speak only as of the date hereof and the Company expressly disclaims any obligation
or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change
in the Company's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements